Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 2/20 | 0.42 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | POLG | P54098 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.39 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | FUT6 | P51993 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503455 | 0.94 | ALDH1A1 (0.45) | ALDH1A1TGM2KRASFUT5P2RY2 | |
| SCHEMBL17198375 | 0.87 | ALDH1A1 (0.56) | ALDH1A1TAS1R3TAS1R1PNPLMNA | |
| SCHEMBL17198456 | 0.85 | TGM2 (0.58) | ALDH1A1TGM2KRASFUT5P2RY2 | |
| SCHEMBL18503430 | 0.83 | TGM2 (0.49) | TGM2KRASFUT5P2RY2P2RY4 | |
| SCHEMBL30619682 | 0.83 | TGM2 (0.57) | TGM2KRASFUT5P2RY2P2RY4 | |
| SCHEMBL6041234 | 0.82 | TGM2 (0.58) | TGM2KRASFUT5P2RY2P2RY4 | |
| SCHEMBL6041236 | 0.82 | TGM2 (0.58) | TGM2KRASFUT5P2RY2P2RY4 | |
| SCHEMBL18503529 | 0.81 | TGM2 (0.58) | TGM2KRASFUT5P2RY2P2RY4 | |
| SCHEMBL25720717 | 0.80 | POLG (0.54) | ALDH1A1TGM2KRASFUT5P2RY2 | |
| SCHEMBL18503426 | 0.79 | ALDH1A1 (0.49) | ALDH1A1PNPLMNATHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | ALDH1A1 1322/4885TGM2 3677/4885KRAS 106/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | ALDH1A1 1311/4885TGM2 3639/4885KRAS 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.